Search 

Humanwell is the market leader in anaesthetics/analgesics, fertility regulation drugs, and Uyghur medicine in Asia. It is also a major player with expanding product portfolio and market shares in treating central nerve system, respiratory and dermatological diseases in China.

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders

Founded in March 2017, IASO BIO is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a total of 7,000㎡ of R&D platform and GMP pilot platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 350 staff.

A clinical stage bio pharmaceutical company focus on immunotherapy of tumor and autoimmune diseases.

Private Equity investment platform of ICBC.

ICBC Asia investment is a wholly-owned holding equity investment platform of industrial and commercial bank of China (ICBC). Managing over 44 billion yuan unlist equity investment. Direct investment over 172 projects, indirect investment in over 2400 companies.

Founded in June 2019, with a focus on high-performance medical devices, the Innovation Center of High-Performance Medical Device is devoted to boosting collaboration as well as in-depth integration and innovation of the "Clinical Practice - Scientific Research - Industry - Market"
ecosystem to build high-quality industrial clusters of medical devices by aggregating and utilizing the innovation resources of the Guangdong-Hong Kong-Macao Greater Bay Area and also international resources based on solid clinical practice and industrial basis of Guangdong Province.

IHM-GBA is short for Innovation center of High-performance Medical device in Greater Bay Area. It's based in Guangzhou of Guangdong province in China. We focus on investment, partnership, and collaboration in global disruptive technology in medical device. We aim at helping global startups to enter into and develop the Chinese market. We are in comprehensive discussion with companies in terms of investment, partnership, licensing, and others.

Illumina is a provider of Next Generation Sequencing technology

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

A VC Capital focused on potential collaborations with and investments in early stage biotech.